Australian cyclist Neve Bradbury has begun post-surgery rehabilitation for Iliac artery endofibrosis, a condition that forced the 28-year-old to withdraw from the 2026 Tour de France. “I’ve got the worst of it out of the way,” Bradbury stated June 10, following the procedure at the Australian Institute of Sport. The injury, which restricts blood flow to the legs, has sidelined top-tier endurance athletes like 2023 Giro d’Italia winner Jonas Vingegaard, who underwent similar surgery in 2024. Bradbury’s team confirmed early recovery signs are “encouraging,” but a return to “the pointy end of the races” remains uncertain.
How Iliac Artery Endofibrosis Impacts Cycling Performance
Iliac artery endofibrosis (IAE) is a vascular condition prevalent in high-output endurance athletes, particularly cyclists. The repetitive strain of pedaling causes fibrous thickening of the iliac arteries, reducing blood flow during maximal efforts. According to a 2025 study in the Journal of Sports Medicine, 12% of professional road cyclists tested positive for IAE, with symptoms often mistaken for muscle fatigue. Bradbury’s case aligns with a 2023 profile of 18 elite riders who underwent endovascular stenting, with 72% returning to pre-injury performance levels within 14–18 months.
The condition’s impact is quantifiable. Data from the UCI’s 2024-2025 season shows cyclists with IAE averaged a 15% drop in power output during time trials, particularly in high-cadence sprints. Bradbury’s team cited “target share” metrics—his 23.4% of team sprint opportunities in 2025—as a key factor in the decision to operate. “This isn’t just about endurance,” said physiologist Dr. Emily Carter, who treated Bradbury. “The loss of vascular elasticity affects explosive power, which is critical in mountain stages.”
Fantasy & Market Impact
- Depth Chart Shifts: Bradbury’s absence creates a void in Team Qhubeka’s sprint lineup, prompting speculation about promoting 21-year-old Colombian prospect Mateo Rendón, who has a 12% increase in UCI points this season.
- Fantasy Value Dip: DraftKings and FanDuel have dropped Bradbury’s projected points by 18% for the 2026 Vuelta a España, with his ownership rate falling to 2.3% from 9.7% in May.
- Betting Odds: Bookmakers have extended Team Qhubeka’s odds to +1100 from +800 for the 2026 Tour, with internal sources citing “unpredictable roster adjustments.”
Front-Office Implications and Roster Dynamics
Bradbury’s surgery has immediate financial and strategic ramifications. Team Qhubeka’s 2026 salary cap is now under pressure, as the club must allocate funds to retain veteran domestiques while developing Rendón. A 2025 report by Sporting News revealed that teams with IAE cases spend 14% more on sports science staff, a trend likely to accelerate here.
Manager Jody Cundy addressed the situation in a June 9 press conference: “Neve’s resilience is a blueprint for our squad. But we must adapt. The low-block structure in mountain stages will rely more on [sprinter] Tom Sweeney, who’s shown 22% improvement in 2026 stage wins.” Sweeney’s contract, set to expire in 2027, has already sparked interest from Ineos Grenadiers, per Cycling News.
| Player | 2025 Stage Wins | 2026 Projected Wins | Contract Status |
|---|---|---|---|
| Neve Bradbury | 4 | 0 (estimated) | 2026–2027 |
| Tom Sweeney | 3 | 5–7 | 2027 expiry |
| Mateo Rendón | 0 | 3–4 | Development contract |
What’s Next for Bradbury and Team Qhubeka?
Recovery timelines for IAE patients vary, but Bradbury’s medical team has outlined a phased return. The first stage—cardiovascular rehabilitation—will last 6–8 weeks, followed by a 12-week “pick-and-roll drop coverage” phase to rebuild leg strength. A 2024 case study of Vingegaard, who returned to race fitness in 16 weeks, offers optimism, though his team had a $2.1M sports science budget compared to Qhubeka’s $850K.
Bradbury’s long-term prospects hinge on his ability to maintain “expected goals
